Xspray Pharma AB has signed a manufacturing and supply agreement with NerPharMa to manufacture its lead product candidate, HyNap-Dasa.    The agreement covers the clinical and world-wide commercial supply of HyNap-Dasa, and includes production of both drug substance and the finished product. HyNap-Dasa is one of three product candidates that Xspray currently has under development. The company’s goal is to launch it in the US market in 2021.    Under the terms of the agreeme...